Gulf International Bank UK Ltd lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 59,614 shares of the pharmaceutical company’s stock after buying an additional 805 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Vertex Pharmaceuticals were worth $10,965,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Resources Investment Advisors Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $27,000. Oregon Public Employees Retirement Fund lifted its stake in shares of Vertex Pharmaceuticals by 16,530.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after buying an additional 4,583,156 shares in the last quarter. We Are One Seven LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $32,000. Berman Capital Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $35,000. Finally, Sontag Advisory LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $36,000. Institutional investors own 95.37% of the company’s stock.

VRTX stock traded up $0.09 during mid-day trading on Thursday, hitting $167.06. The company had a trading volume of 85,673 shares, compared to its average volume of 1,450,118. The stock has a market cap of $42.69 billion, a P/E ratio of 58.17, a PEG ratio of 2.67 and a beta of 1.64. Vertex Pharmaceuticals Incorporated has a 12-month low of $144.07 and a 12-month high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.24. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The firm had revenue of $870.11 million for the quarter, compared to the consensus estimate of $818.29 million. During the same period in the previous year, the firm posted $0.61 EPS. The business’s quarterly revenue was up 33.5% on a year-over-year basis. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.04 EPS for the current fiscal year.

A number of research firms recently weighed in on VRTX. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, March 8th. ValuEngine cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Evercore ISI assumed coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, April 11th. They issued an “in-line” rating and a $183.00 price target on the stock. Finally, Svb Leerink reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $203.31.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 5,624 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $181.75, for a total value of $1,022,162.00. Following the transaction, the executive vice president now directly owns 36,272 shares in the company, valued at approximately $6,592,436. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey M. Leiden sold 111,431 shares of the company’s stock in a transaction dated Monday, February 11th. The stock was sold at an average price of $180.24, for a total transaction of $20,084,323.44. Following the completion of the transaction, the chief executive officer now owns 223,916 shares in the company, valued at $40,358,619.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 211,241 shares of company stock worth $38,636,134. Insiders own 0.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Gulf International Bank UK Ltd Has $10.97 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2019/04/18/gulf-international-bank-uk-ltd-has-10-97-million-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.